Asenapine

CHEMBL3187365 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

285.8 g/mol

LogP

3.8

Phase

4

An atypical antipsychotic that blocks multiple dopamine and serotonin receptor subtypes in the brain to reduce psychotic symptoms and mood instability in schizophrenia and bipolar disorder. The sublingual formulation is absorbed through the mouth lining to bypass first-pass metabolism.

Moleküler Ağırlık

285,8000 g/mol

LogP

3,80

TPSA

12,50 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Schizophrenia Bipolar Disorder Gastroesophageal Reflux Disease Stroke Major Depressive Disorder

Etki Mekanizması

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1

InChI

InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3

Molecular Formula

C17H16ClNO

HBD / HBA

- / 2

Döndürülebilir Bağlar

0

Ağır Atomlar

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

An atypical antipsychotic that blocks multiple dopamine and serotonin receptor subtypes in the brain to reduce psychotic symptoms and mood instability in schizophrenia and bipolar disorder. The sublingual formulation is absorbed through the mouth lining to bypass first-pass metabolism.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Asenapine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3187365. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 163091. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Asenapine PillFYI'da

Yapı

Hızlı Veriler

Formül: C17H16ClNO
Eş Anlamlılar: 2

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.